Strata Skin Sciences (Strata Skin Sciences) Cash-to-Debt : 0.43 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Strata Skin Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Strata Skin Sciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.43.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Strata Skin Sciences couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Strata Skin Sciences's Cash-to-Debt or its related term are showing as below:

SSKN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17 Med: 0.79 Max: 2.29
Current: 0.43

During the past 13 years, Strata Skin Sciences's highest Cash to Debt Ratio was 2.29. The lowest was 0.17. And the median was 0.79.

SSKN's Cash-to-Debt is ranked worse than
74.91% of 861 companies
in the Medical Devices & Instruments industry
Industry Median: 1.91 vs SSKN: 0.43

Strata Skin Sciences Cash-to-Debt Historical Data

The historical data trend for Strata Skin Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Strata Skin Sciences Cash-to-Debt Chart

Strata Skin Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.94

0.97

1.57

0.64

0.43

Strata Skin Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.64	0.34	0.57	0.45	0.43

Competitive Comparison of Strata Skin Sciences's Cash-to-Debt

For the Medical Devices subindustry, Strata Skin Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Strata Skin Sciences's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Strata Skin Sciences's Cash-to-Debt falls into.

Strata Skin Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Strata Skin Sciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.784	/	(0.352	+	15.281)
	=	0.43

Strata Skin Sciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.784	/	(0.352	+	15.281)
	=	0.43

Strata Skin Sciences (NAS:SSKN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Strata Skin Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Strata Skin Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Strata Skin Sciences (Strata Skin Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Strata Skin Sciences Inc (NAS:SSKN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

E2OM:Germany E2OM:Germany

Address

5 Walnut Grove Drive, Suite 140, Horsham, PA, USA, 19044

Website

https://www.strataskinsciences.com

Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United states.

Executives

Shmuel Gov	officer: SVP & General Manager Carlsbad	5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Samuel Rubinstein	director	5 WALNUT GROVE DR., SUITE 140, HORSHAM PA 19044
Wayne Cafran	director	5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Irit Yaniv	director	5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
22nw Gp, Inc.	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
22nw Fund Gp, Llc	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Aron R. English	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
22nw, Lp	10 percent owner	590 1ST AVE S, UNIT C1, SEATTLE WA 98104
22nw Fund, Lp	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Christopher Lesovitz	officer: Chief Financial Officer	5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Robert Joseph Moccia	director, officer: Chief Executive Officer	5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
William D. Humphries	director	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Patricia S Walker	director	5540 EKWILL ST STE D, SANTA BARBARA CA 93111
Douglas Strang	director	5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Nachum Shamir	director	12212 TECHNOLOGY BLVD, AUSTIN TX 78727